The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual growth rate (CAGR) of 5.8 percent, according to a new report by Grand View Research, Inc., a research firm based in San Francisco. Rising demand for minimally invasive surgical procedures is a major factor expected to boost the market during the forecast period. These devices assist surgeons in accurate insertion of contrast agents with reduced human errors, thus increasing the accuracy and efficiency of surgical procedures. They play a crucial role in intra-operative computed tomography (iCT), intra-operative magnetic resonance imaging (iMRI) and interventional cardiology. Availability of advanced injector systems for diagnosis and intra-operative imaging has boosted adoption of these systems.

Technological advances — particularly the adoption of 3-D digital breast tomosynthesis (DBT) — are making it possible for earlier, and more accurate, detection of breast cancer. However, the transition to 3-D mammography is resulting in numerous challenges and concerns. DBT produces hundreds of images, compared to just four images typically associated with conventional 2-D digital mammography. As a result, radiologists find they require significantly more time to review and interpret each exam, reducing the number of patients they can see each day and increasing fatigue, which could potentially lead to missed diagnoses.